Mallinckrodt is partnering with admedicum
Lung Cancer Europe shared on X:
“Mallinckrodt, a patient-focused pharmaceutical company, is partnering with admedicum, a patient engagement expert, to launch a collaborative project focused on immune-related colitis, a complication of ICI treatment.
As Mallinckrodt is developing a potential new treatment for immune-related colitis, this project aims to involve patients early on by forming a focus group to discuss:
- symptoms and burden of immune-related colitis
- unmet needs of patients experiencing this complication.
The project is seeking:
- Melanoma or lung cancer patients who experienced or are experiencing colitis as a side effect of ICI treatment and have received treatment for it
- Patient reps from advocacy groups with experience/knowledge of immune-related colitis in ICI patients
The first virtual focus group meeting is planned for late June/early July 2024 and will last 3-4 hours. Participants will receive preparation materials beforehand. Subsequent meetings and tasks will be discussed during the first meeting, with participation optional.
Compensation will be provided for attending meetings and any preparatory/follow-up activities.
If interested in taking part of the project or need more information, please contact Razak Ellafi at [email protected].”
Source: Lung Cancer Europe/X
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023